Summary
Thermo Fisher Scientific Inc. (TMO) reported strong financial results for the second quarter and first six months of 2019. Total revenues increased year-over-year, driven by growth across most segments, particularly Life Sciences Solutions and Laboratory Products and Services. A significant factor contributing to the improved profitability was the substantial gain from the divestiture of the Anatomical Pathology business, which boosted net income and operating income. The company also demonstrated solid cash flow from operations, enabling continued investment in acquisitions and shareholder returns. Despite foreign currency headwinds, Thermo Fisher's core business operations showed resilience and growth, underscoring its market leadership and strategic execution. Looking ahead, the company expressed confidence in its liquidity and ability to meet future cash requirements, supported by existing cash reserves, operational cash flow, and available credit facilities. Management's focus remains on driving organic growth through strategic investments in commercial capabilities and R&D, while also evaluating complementary acquisitions. The company's diverse portfolio and global reach position it well to navigate market dynamics and capitalize on emerging opportunities in the life sciences and healthcare sectors.
Financial Highlights
55 data points| Revenue | $6.32B |
| Gross Profit | $2.82B |
| R&D Expenses | $246.00M |
| SG&A Expenses | $1.56B |
| Operating Expenses | $4.82B |
| Operating Income | $1.50B |
| Interest Expense | $181.00M |
| Net Income | $1.12B |
| EPS (Basic) | $2.80 |
| EPS (Diluted) | $2.77 |
| Shares Outstanding (Basic) | 400.00M |
| Shares Outstanding (Diluted) | 403.00M |
Key Highlights
- 1Total revenues for the six months ended June 29, 2019, increased to $12.44 billion from $11.93 billion in the prior year period, representing a 4% increase.
- 2Net income for the six months ended June 29, 2019, rose to $1.93 billion, a significant increase from $1.33 billion in the comparable 2018 period, driven largely by a gain on sale of a business.
- 3Operating income for the six months ended June 29, 2019, surged to $2.42 billion, up from $1.72 billion in the prior year, primarily due to the gain on the sale of the Anatomical Pathology business and higher sales.
- 4The company completed the acquisition of Brammer Bio for approximately $1.7 billion in cash, expanding its contract manufacturing capabilities for gene and cell therapies.
- 5Thermo Fisher successfully divested its Anatomical Pathology business for $1.13 billion, resulting in a pre-tax gain of approximately $505 million.
- 6Cash flow from operating activities for the six months ended June 29, 2019, was strong at $1.94 billion, an increase from $1.52 billion in the same period of 2018, supported by improved working capital management.
- 7The company maintained a healthy cash position, with cash, cash equivalents, and restricted cash totaling $2.31 billion as of June 29, 2019.